NCT06777602View on ClinicalTrials.gov

A Clinical Study To Understand How Radiolabeled MK-5475 Is Taken Up By The Body, Broken Down And Then Removed From The Body in Healthy Participants (MK-5475-011)

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

August 15, 2022

Primary Completion Date

September 30, 2022

Study Completion Date

October 25, 2022

Conditions
Healthy
Interventions
DRUG

[14C] MK-5475

\[14C\] MK-5475 is administered as a single IV bolus dose in healthy male participants on Day 1.

Trial Locations (1)

53704

Labcorp Clinical Research Unit Inc. (Site 0001), Madison

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY